## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.4% below STRENGTH zone (4.0-10.0%); PEG 4.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($667.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Guggenheim Capital LLC Purchases 3,577 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251206T113358 | Somewhat-Bullish | Relevance: 98%
-  Guggenheim Capital LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.3% in the second quarter, now owning 21,169 shares valued at $11.354 million. Other institutional investors also adjusted their positions, and insiders, including EVP Nimrata Hunt, have recently sold a significant number of shares. IDEXX Laboratories reported strong quarterly earnings and revenue, surpassing analyst estimates, and has received a "Moderate Buy" consensus rating from analysts with an average target price of $730.50.

**2. IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Rating of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251209T070825 | Bullish | Relevance: 98%
- IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $763.50. The company recently exceeded quarterly earnings estimates, reporting $3.22 EPS against an expected $3.14, and generated $1.11 billion in revenue, beating forecasts of $1.07 billion. Insider selling by EVP Nimrata Hunt (9,425 shares at $703.34) reduced her stake by 30.8%, while institutional investors hold a significant 87.84% of the company's stock.

**3. IDEXX Laboratories, Inc. $IDXX Shares Purchased by California Public Employees Retirement System**
- Source: MarketBeat | 20251209T102318 | Somewhat-Bullish | Relevance: 98%
- The California Public Employees Retirement System increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.7% in the second quarter, bringing its total holdings to 148,408 shares valued at $79.6 million. Other institutional investors also adjusted their positions, while an IDEXX executive recently sold over 9,000 shares. The company reported strong Q3 earnings, exceeding analyst expectations, and has a consensus "Moderate Buy" rating from analysts.

**4. First Trust Advisors LP Purchases 35,526 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251206T093431 | Bullish | Relevance: 98%
-  First Trust Advisors LP increased its holdings in IDEXX Laboratories, Inc. by 16.2% during the second quarter, acquiring an additional 35,526 shares. This strategic move brings their total ownership to 254,553 shares, valued at approximately $136.5 million. The article also details institutional ownership, stock performance, recent analyst ratings, and insider trading activity for IDEXX Laboratories.

**5. Edgestream Partners L.P. Has $1.48 Million Holdings in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251207T030928 | Bullish | Relevance: 97%
-  Edgestream Partners L.P. significantly reduced its stake in IDEXX Laboratories, Inc. by 87.0% in the second quarter, selling 18,507 shares to hold 2,755 shares valued at $1.478 million. This comes as IDEXX Laboratories reported strong quarterly earnings, beating analyst estimates with $3.22 EPS and $1.11 billion in revenue, and issued optimistic FY2025 guidance. Corporate insiders currently own about 0.98% of the stock, with an EVP recently selling a substantial number of shares.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.2x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.22 signals overvaluation risk, limited margin of safety. Forward P/E 49.0x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.5B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.22 |
| Forward P/E | 49.0 |
| Current P/E | 54.8 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.5% to -3.4% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.4pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). MACD histogram bearish (-4.58), momentum weakening. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.38% (CS: 28) | Weak |
| RSI_14 | 50.0 | Neutral |
| MACD Histogram | -4.58 | Bearish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 1.047x | Above |
| vs SMA200 | 1.260x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $706.65
- **Stop Loss:** $667.39 (5.6% risk)
- **Target:** $745.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $8,479.80
- **Portfolio %:** 8.48%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*